Investment overview
Suntop Healthcare both operates dialysis centers and builds its own medical platform — that combination is what separates us from our peers.
Our position
The industry has chain operators focused on expansion and software companies focused on systems. We are neither. We first rebuilt our own dialysis centers into smart dialysis centers — precision management, a smart supply chain, AI and IoT introduced as one package — and then brought that capability to partner hospitals. A software vendor has no clinical setting of its own in which to prove anything; a chain operator replicates centers rather than capability. What we replicate is a way of working that can be installed inside somebody else's center. The system is developed in-house by Daite Intelligent Technology, a wholly owned subsidiary that holds the registration. It embeds deeply into hospital workflow, making it costly to replace, while growing data volume continues to improve model accuracy.
Current scale
System × Supply chain × Endpoint
These three segments are rarely held by one company in the Chinese dialysis market. Software vendors have no centers of their own; device and consumables manufacturers do not own the clinical workflow; chain operators have neither. Each segment held makes the other two worth more.
System
A registered dialysis information system, device IoT and clinical decision support applications, developed in-house by Daite Intelligent Technology, a wholly owned subsidiary. The system is what allows the way one center works to be reproduced at the next.
Class II medical device registration held
Supply chain
One-stop supply of dialyzers, bloodlines, machines and water treatment, with online ordering, shipment tracking and traceability to the original batch. Procurement scale sets our cost, and cost sets the terms we can offer a partner.
Among the largest single private purchasers in China
Endpoint
Self-operated dialysis centers and hospitals, together with centers co-established with partner hospitals. The endpoint is both a source of revenue and the setting where new capability is validated before it is offered elsewhere.
Self-operated and partner center network
Who holds which segment
| Market participant | System | Supply chain | Endpoint |
|---|---|---|---|
| Information system / software vendors | ✓ | — | — |
| Device and consumables manufacturers | — | ✓ | — |
| Chain dialysis operators | — | — | ✓ |
| Public hospital dialysis units | — | — | ✓ |
| Suntop Healthcare | ✓ | ✓ | ✓ |
This table is Suntop's own summary of market structure, offered to explain how our position differs. It is not an assessment of any particular company.
Market opportunity
China's dialysis treatment rate remains well below that of neighbouring high-income economies. Measured in patients per million population, China stands at roughly one third of Japan and one fifth of Taiwan. That gap means the treated dialysis population in China will continue to grow for the foreseeable future.
Each figure is taken from the most recent year its national registry has published, so the years are not aligned. The figure for China is derived from the patient count and national population; the other three are rates published directly by their registries. The chart is intended to show the order of the difference, not to support precise comparison.
Policy environment
Over the past two years every reform on the payment side has landed directly on dialysis. Together they have compressed the room to operate on product margin, while raising the bar for operations and compliance — pressure for those who cannot meet it, and a barrier protecting those who can.
Volume-based procurement
Inter-provincial alliance procurement of blood purification consumables took effect in June 2024, with reductions of up to 74%; a Beijing-Tianjin-Hebei alliance followed in 2025 at an average of 55.23%. Margin on consumables has been compressed systematically.
Payment reform
The DRG/DIP 2.0 grouping scheme has applied uniformly across pooling regions since January 2025, adding continuing cost-control and compliance pressure on providers.
Price item restructuring
The provisional guide to urinary-system service pricing consolidated dialysis items into 108 entries and folded the cost of monitoring during treatment into the base treatment price, effective August 2025.
AI enters policy and the pricing system
In November 2025 five ministries issued implementing opinions on promoting and regulating AI in healthcare; the National Healthcare Security Administration has also listed AI assistance as an extension item within its pricing guides.
Sources: documents published by the National Healthcare Security Administration and the National Health Commission; years are given in each entry. These are statements of policy as issued, not forecasts of where policy will go.
Business model
Dialysis services
Treatment revenue from self-operated and partner centers.
Systems and platform
Sale, deployment and ongoing service of the dialysis management system.
AI usage fees
Charged per treatment session to centers using the AI capabilities.
Equipment and consumables
Supply of dialysis equipment and consumables, integrated with the system interfaces.
Smart supply chain
Procurement, warehousing and distribution across the center network.
Compliance and governance
Our software holds a Class II medical device registration from the People's Republic of China. Every product capability is labelled with the regulatory tier it sits in, separating what is within the registered scope, what is clinical decision support, and what remains in research validation.
View registration and complianceRequest detailed materials
Financial projections, expansion plans and the full investment materials are provided on request following review. Please tell us about your firm and where your interest lies.
Available on request
- Full company profile (PDF)
- Financial projections and the three-year expansion plan
- Smart dialysis center deployment progress and roadmap detail
- Supply chain and product catalogue
Any forward-looking content in these materials reflects planning assumptions and does not constitute a commitment or a guarantee of returns.